We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Geovax Labs Inc is us-based clinical-stage biotechnology company. Geovax Labs Inc is us-based clinical-stage biotechnology company.
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies...
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that...
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and...
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance...
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against...
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced...
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today...
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.16 | 7.17488789238 | 2.23 | 2.68 | 2.23 | 741700 | 2.5311243 | CS |
4 | -0.24 | -9.12547528517 | 2.63 | 3.15 | 2.17 | 932227 | 2.72572998 | CS |
12 | -0.3 | -11.1524163569 | 2.69 | 3.88 | 1.75 | 1719042 | 2.82958467 | CS |
26 | 0.9 | 60.4026845638 | 1.49 | 11.18 | 1.0901 | 4279247 | 4.6111458 | CS |
52 | -2.2915 | -48.9479867564 | 4.6815 | 11.18 | 1.0901 | 2223154 | 4.57611862 | CS |
156 | -55.81 | -95.8934707904 | 58.2 | 64.5 | 1.0901 | 3706182 | 25.45929626 | CS |
260 | -42.61 | -94.6888888889 | 45 | 130.65 | 1.0901 | 3074929 | 32.45905368 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions